回盛生物 (300871)

WUHAN HVSEN BIOTECHNOLOGY CO.,LTD.

ASZ

Tags

Agriculture, Forestry, Animal Husbandry, and FisheryHigh-Performing StocksMargin Trading and Securities LendingAnimal Health IISZSE Medicine Equal Weight IndexAnimal Husbandry & Breeding IndexShenzhen A-Share Pharmaceutical IndexHubei IndexChiNext Composite IndexChiNext Registration SystemConvertible Bond IssuersAugust 2021 Lock-up ExpiryQFII HoldingsShareholding Increase CommitmentInsurance Heavy HoldingsFull Circulation SharesStocks Below Book ValueCNI 2000 IndexNew IndexManufacturing IndexChiNext Quality Index

K-Line Chart

No K-line data available

Company NameWuhan Huisheng Biotechnology Co., Ltd.
Listing Date2020-08-24
Issue Price33.61RMB
Registered Capital20233.255710k RMB
Legal RepresentativeZhang Weiyuan
Registered AddressNo. 52 Yousha Road, Xingou Street Office, Dongxihu District, Wuhan City, Hubei Province
IndustryAnimal Health II
Main BusinessResearch, development, production, and sales of veterinary drugs (including chemical drug preparations, active pharmaceutical ingredients, traditional Chinese medicine preparations), feed, and additives.
Company ProfileWuhan Huisheng Biotechnology Co., Ltd. is a high-tech enterprise specializing in the animal health sector, integrating R&D, production, and sales. It serves as the supporting unit for the Hubei Provincial Veterinary Drug Engineering Technology Research Center and has been recognized as the "Hubei Provincial Enterprise Technology Center." The company has successively established R&D platforms such as the "Academician Expert Workstation" and "Postdoctoral Workstation," and has taken the lead in forming the "Strategic Alliance for Technological Innovation in the Veterinary Drug Preparation Industry." While continuously improving and solidifying its own R&D capabilities, the company engages in extensive and in-depth cooperation with major universities and research institutes, establishing a stable industry-academia-research collaboration mechanism in the field of veterinary drug innovation. The company founded a professional swine disease research institution—the Huisheng Swine Disease Research Institute—which provides professional swine disease testing and diagnosis, as well as personalized swine disease prevention and control solutions to farms using advanced technological methods and concepts.

Stock Details

1. Key Indicators

  • Total Shares(W): 20233.26
  • Circulating A-Shares(W): 20233.26
  • Earnings Per Share(RMB): 1.0134
  • Net Assets Per Share(RMB): 10.4204
  • Operating Revenue(W RMB): 125953.40
  • Total Profit(W RMB): 21458.78
  • Net Profit Attributable to Parent(W RMB): 18790.63
  • Net Profit Growth Rate(%): 494.28
  • Weighted Return on Equity(%): 10.3500
  • Operating Cash Flow Per Share(RMB): 0.8970
  • Undistributed Profit Per Share(RMB): 2.0932
  • Capital Reserve Per Share(RMB): 7.1719

2. Main Business

The main business covers:

  • Veterinary Drugs (including chemical preparations, APIs, and traditional Chinese medicine preparations)
  • Feed and Additives

3. Company Basic Information

  • Company Name: Wuhan Hvsen Biotechnology Co., Ltd.
  • Listing Date: 2020-08-24
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 1 Zhonghua Road, Wuchang District, Wuhan City, Hubei Province
  • Website: www.whhsyy.com
  • Company Profile：On November 15, 2016, all shareholders of the company signed the "Sponsor Agreement", agreeing to restructure Hvsen Co., Ltd. into a joint stock company based on the audited net assets as of August 31, 2016. According to the audit report issued by ZhongShen ZhongHuan, the audited net asset value of the company was 136.7539 million yuan, of which 80 million yuan was converted into the share capital of the joint stock company, and the remaining 56.7539 million yuan was included in the capital reserve. On December 10, 2016, ZhongShen ZhongHuan verified the above matters and issued the capital verification report. On December 23, 2016, Hvsen Biotechnology obtained the business license issued by the Hubei Provincial Administration for Industry and Commerce. On December 28, 2016, the Wuhan Municipal Bureau of Commerce issued the "Foreign-invested Enterprise Change Filing Receipt" for the above matters.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Wuhan Tongsheng Investment Co., Ltd. General Legal Person 8280.00 40.92
2 Beijing Jiuzhou Wanli Investment Co., Ltd. General Legal Person 106.00 0.52
3 Wuhan Hvsen Biotechnology Co., Ltd.-2023 Employee Stock Ownership Plan Asset Management Plan 98.14 0.49
4 Wanjia CSI 2000 Index Enhanced Securities Investment Fund Class A Fund 0.84 0.00

5. Concept Sectors

  • Innovative Drugs
  • Synthetic Biology
  • Pet Economy
  • Margin Trading & Securities Lending
  • High-Performance Stock
  • ChiNext Quality

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information